STLN trades 155.0% below Wall Street's consensus target of $8.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes STLN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 18, 2026, Starling Oncology, Inc. (STLN) has a Wall Street consensus price target of $8.67, based on estimates from 5 covering analysts. With the stock currently trading at $3.40, this represents a potential upside of +155.0%. The company has a market capitalization of $340M.
Analyst price targets range from a low of $7.00 to a high of $10.00, representing a 35% spread in expectations. The median target of $9.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, STLN trades at a trailing P/E of -100.3x. Analysts expect EPS to grow -307.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
AIOTPowerFleet, Inc. | $277M | $2.06 | $7.40 | +260.1% | Buy | — | 6 |
ONCOOnconetix, Inc. | $1M | $3.00 | — | — | — | — | — |
USPHU.S. Physical Therapy, Inc. | $1.5B | $97.34 | $90.00 | -7.5% | Buy | 34.2x | 13 |
OPCHOption Care Health, Inc. | $5.0B | $31.63 | $28.31 | -10.5% | Hold | 16.8x | 16 |
ADUSAddus HomeCare Corporation | $2.3B | $121.56 | $128.75 | +5.9% | Buy | 17.2x | 18 |
AMSFAMERISAFE, Inc. | $364M | $19.44 | $33.50 | +72.3% | Buy | 10.4x | 6 |
MCKMcKesson Corporation | $127.4B | $1091.67 | $983.13 | -9.9% | Buy | 24.5x | 31 |
CAHCardinal Health, Inc. | $65.4B | $279.25 | $279.33 | +0.0% | Buy | 22.2x | 33 |
VEEVVeeva Systems Inc. | $46.9B | $288.41 | $300.50 | +4.2% | Buy | 31.2x | 43 |
DOCSDoximity, Inc. | $5.8B | $31.11 | $27.73 | -10.9% | Hold | 23.1x | 24 |
Quick answers to the most common questions about buying STLN stock.
The consensus Wall Street price target for STLN is $8.67, representing 155.0% upside from the current price of $3.4. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
STLN has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $8.67 implies 155.0% upside from current levels.
STLN's current price is $3.4 with a consensus target of $8.67 (155.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $10 for STLN, while the most conservative target is $7. The consensus of $8.67 represents the median expectation. These targets typically reflect 12-month expectations.
STLN is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month STLN stock forecast based on 5 Wall Street analysts shows a consensus price target of $8.67, with estimates ranging from $7 (bear case) to $10 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on STLN, with a "Buy" consensus rating and $8.67 price target (155.0% upside). 5 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
STLN analyst price targets range from $7 to $10, a 35% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $8.67 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.